Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Target Occupancy in Triple-Negative Breast Cancer: A Medicinal Chemistry Perspective on Modality-Guided Design for Durable Network Control.

Journal of medicinal chemistry·2026
Same author

Copper Transporter 1‑Mediated Deregulation of Copper Homeostasis Impacts MYC and Oxidative Phosphorylation Pathways and Increases the Sensitivity of Tumor Cells to Complex I Inhibitors.

ACS pharmacology & translational science·2026
Same author

Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.

ACS pharmacology & translational science·2026
Same author

Dioscin Suppresses Ovarian and Gastric Tumor Progression by Inhibiting ALDH1A3-Mediated Retinoic Acid Metabolism and Cancer Stemness.

Phytotherapy research : PTR·2026
Same author

Ferroptosis and Autophagy-Dependent Cell Death in Oncology Medicinal Chemistry: Call for Papers.

Journal of medicinal chemistry·2026
Same author

Guizhi-Fuling Wan suppresses carcinoma-associated mesenchymal stem cells-induced ovarian cancer progression via STAT3 inhibition.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2025

Related Experiment Video

Updated: Jun 4, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Allosteric inhibitor development targeting HIV-1 integrase.

Laith Q Al-Mawsawi1, Nouri Neamati

  • 1Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, California 90089, USA. almawsawi@gmail.com

Chemmedchem
|January 29, 2011
PubMed
Summary

New HIV-1 integrase inhibitors targeting allosteric sites offer hope against drug-resistant strains. This approach may overcome limitations of current strand-transfer inhibitors and improve HIV therapy options.

More Related Videos

Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Related Experiment Videos

Last Updated: Jun 4, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Area of Science:

  • Virology
  • Drug Discovery
  • Medicinal Chemistry

Background:

  • HIV-1 integrase (IN) is a key target for antiretroviral therapy.
  • Strand-transfer inhibitors like raltegravir and elvitegravir are FDA-approved or in late-stage trials.
  • Emergence of drug-resistant HIV-1 strains necessitates novel therapeutic strategies.

Purpose of the Study:

  • To review the concept of allosteric inhibition of HIV-1 integrase.
  • To explore small molecules targeting non-active-site regions of IN.
  • To address the challenge of HIV-1 strand-transfer inhibitor resistance.

Main Methods:

  • Literature review of allosteric IN inhibitors.
  • Analysis of small molecules targeting non-active-site IN regions.
  • Discussion of therapeutic implications for HIV-1 treatment.

Main Results:

  • Allosteric IN inhibitors offer a promising strategy against resistant HIV-1 strains.
  • These inhibitors may overcome cross-resistance issues associated with strand-transfer inhibitors.
  • Allosteric inhibitors could potentially synergize with existing HIV-1 therapeutics.

Conclusions:

  • Allosteric inhibition represents a viable approach for developing next-generation HIV-1 integrase inhibitors.
  • Targeting allosteric sites may provide effective options for treatment-experienced patients.
  • Further research into allosteric IN inhibitors is crucial for advancing HIV therapy.